1 Impact of SARS-CoV-2 Infection on Antimicrobial Resistance Gene Profiles in the

2 Upper Respiratory Tract: A Cross-Sectional Study

- 3
- 4 Authors: Siddharth Singh Tomar^{1,2} & Krishna Khairnar^{1,2}*
- Author Affiliation: ¹Environmental Epidemiology and Pandemic Management (EE&PM), Council of
 Scientific and Industrial Research-National Environmental Engineering Research Institute (CSIR-NEERI),
- 7 Nagpur, India.
- 8

12 13

- ² Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, UP, India.
- 10 *Corresponding author: Correspondence to Krishna Khairnar
- 11 e-mail: <u>k_khairnar@neeri.res.in</u>, <u>kskhairnar@gmail.com</u>

Abstract

14 **Objectives:**

- 15 To investigate the impact of SARS-CoV-2 infection on the antimicrobial resistance (AMR) gene profiles in 16 the upper respiratory tract (URT) and To evaluate variations in AMR gene diversity, abundance, and
- 17 ESKAPE-associated AMR in URT. By comparing SARS-CoV-2-positive patients to healthy controls.

18 19 **Met**

- Methods:
 95 URT swab samples from SARS-CoV-2-positive (n=48) and RTPCR-negative control participants
- (n=47) collected from central India. Metagenomic DNA was extracted, and metagenomic sequencing was
 performed using the Illumina NextSeg550 platform. Sequencing data were analysed using the Chan
- performed using the Illumina NextSeq550 platform. Sequencing data were analysed using the Chan
 Zuckerberg ID pipeline for Antimicrobial resistance (AMR) gene detection and taxonomic profiling. Chao1,
- 24 Shannon and Simpson diversity indices, Bray-Curtis dissimilarity, and Bayesian regression, were used to
- identify significant differences in AMR gene abundance and microbial associations.
- 26

27 Results:

- 28 The Chao1 index (p=0.01651) of SARS-CoV-2 samples indicated significantly higher AMR gene richness 29 than the controls. Resistance genes, such as mecA, blaOXA-48, and blaNDM-1, showed higher 30 abundance in SARS-CoV-2 samples. These genes were found to be linked to high-priority pathogens like 31 Klebsiella pneumoniae, Escherichia coli, and Staphylococcus aureus. Bayesian regression demonstrated 32 that SARS-CoV-2 infection is a significant factor in elevated AMR gene abundance (β = 1.549, HDI 33 [1.409, 1.691]). Females showed higher AMR levels than males ($\beta = 0.261$, HDI [0.167, 0.350]), and the 34 model outputs showed no significant age correlation. Sankey diagrams and heatmaps showed higher 35 AMR gene diversity and abundance in the SARS-CoV-2 group.
- 36

37 Conclusions:

- 38 SARS-CoV-2 infection alters the URT's AMR gene profile and increases the resistance genes' abundance 39 and diversity. The results indicate a requirement to enhance AMR surveillance of COVID-19 patients to 40 adapt antimicrobial stewardship strategies and reduce the chances of secondary infections. It is, 41 therefore, essential to carry out more extensive studies to analyze temporal variations and the effects of 42 antibiotic overuse on AMR evolution.
- 43

Keywords: SARS-CoV-2, antimicrobial resistance, resistome, upper respiratory tract, metagenomics,
 ESKAPE pathogens, antibiotic resistance.

46

1 Introduction

2 The global SARS-CoV-2 pandemic has induced research into its broader effects. This study 3 focuses on the Antimicrobial resistance (AMR) dynamics in the upper respiratory tract (URT) of 4 SARS-CoV-2-infected individuals. The URT is the primary entry point and predisposition site for 5 respiratory viruses. Therefore, URT is an important site for studying AMR diversity in SARS-6 CoV-2-infected individuals. SARS-CoV-2 infection may contribute to dysbiosis of baseline URT 7 flora and promote the spread of AMR genes¹, ²,³. Respiratory viral infections have been shown 8 to alter microbial diversity and contribute to secondary bacterial infections and favoring 9 pathogenic bacteria capable of acquiring resistance .

10 AMR in respiratory infections is a growing concern due to widespread antibiotic use even before 11 the SARS-CoV-2 pandemic. Indiscriminate antibiotic use disrupts the microbial balance and 12 promotes the enrichment of resistant organisms . Respiratory resistomes serve as reservoirs 13 for resistance genes transferable to pathogenic bacteria. Studies have shown that SARS-CoV-2 infection influences microbial communities and resistomes of patients ... Virus-induced 14 15 inflammation and immune suppression promote bacterial growth and enrichment of AMR genes 16 in SARS-CoV-2-positive individuals. Recently, the World Health Organisation has also 17 highlighted the overuse of antibiotics in COVID-19 patients contributing to increasing AMR¹.

18 Microbiome studies on COVID-19 patients reveal shifts in diversity and increased abundance of 19 clinically important pathogens like Staphylococcus aureus and Pseudomonas aeruginosa. 20 These pathogens can acquire resistance to common antibiotics¹¹. The AMR genes like blaKPC, 21 blaNDM, and mecA in COVID-19 patients, responsible for resistance in ESKAPE pathogens, were detected in the resistomes of SARS-CoV-2 positive individuals¹². Despite growing 22 23 evidence of SARS-CoV-2's impact on the resistome, further research is required to fully understand the effects of viral infection on AMR abundance and diversity, for which 24 25 metagenomic sequencing is a valuable tool¹³.

Few studies have investigated the relationship between SARS-CoV-2 infection and changes in the URT resistome in the Indian context. Researchers investigated changes in the URT microbiome of SARS-CoV-2-infected individuals to identify infection-specific signatures for developing nasal prebiotic therapies¹. However, they did not examine AMR alterations in the URT of SARS-CoV-2-positive individuals. This study uses a metagenomic approach to

understand the effect of SARS-CoV-2 infection on URT resistome and abundance of ESKAPE
 pathogens.

3 2. Materials and methods

4 **2.1. Study Population**

The samples used for the study were collected during March-April 2023. The study population 5 6 belongs to the Vidarbha region of Central India, with samples collected from participants across 7 five districts: Nagpur, Wardha, Gadchiroli, Chandrapur, and Bhandara. For the SARS-CoV-2 8 Negative Group (Control), the median age (interguartile range [IQR]) is 29 years (22 to 37). For 9 the SARS-CoV-2 Positive Group, the median age (IQR) is 36 years (19 to 67). Participants from 10 the SARS-CoV-2 group presented with severe acute respiratory infection (SARI) and/or 11 influenza-like illness (ILI) symptoms. While the participants from the control group were asymptomatic and RTPCR negative. 12

13

14 2.2. Sample Collection and Processing

15 In total, 96 URT swab samples in Viral Transport Medium (VTM) were collected for this study, 16 out of which 48 were from SARS-CoV-2 positive individuals (SARS-CoV-2 group) and 48 17 samples were collected from Healthy control (RTPCR negative). These samples were collected 18 by expert healthcare professionals while following the standard sample collection guidelines. 19 The collected samples were maintained at 4 °C \leq 5 days (Short-term storage) and at -80 °C for 20 the long term. Aliquots of these collected samples were then processed for SARS-CoV-2 21 RTPCR testing under Biosafety level-II conditions. Samples with ≤ 25 cycle threshold value of 22 SARS-CoV-2 target genes were considered positive samples.

23

24 2.3. Metagenomic DNA Extraction, Library Preparation, and Metagenomic Sequencing

The metagenomic DNA extraction was done using the QIAamp DNA Microbiome Kit (Catalog No. 51704). The DNA concentration was measured using a Qubit fluorometer. DNA purity was assessed using a Nanodrop spectrophotometer by analyzing the A260/280 and A260/230 ratios. DNA libraries were prepared with the QIAseq FX DNA Library Preparation Kit.

- Metagenomic next-generation sequencing (mNGS) was performed on the NextSeq550 platform
 using a 2x150 bp high-output kit, generating paired-end reads over 300 cycles.
- 3
- 4
- 5

6 2.4. Metagenomic Data Analysis

Metagenomic data analysis was performed using the Chan Zuckerberg ID (CZID) web-based
platform. Sequencing quality control was done by removing External RNA Controls Consortium
(ERCC) sequences with Bowtie2 (Version 2.5.4)¹⁶. Sequencing adapters, short reads, lowquality sequences, and low-complexity regions were filtered using a customized fastp tool¹⁷.
DNA sequences with quality scores < 17, reads shorter than 35 bp, high-complexity sequences
> 40%, and > 15 undetermined bases were excluded.

13

14 The Host (Human) sequences were removed by aligning with Bowtie2 and HISAT2 against reference genomes¹⁸. CZID-dedup was used for 100% identical sequences till the first 70 base 15 pairs. Only one representative read was retained. The STAR algorithm¹⁹ was also used to 16 17 remove duplicate, low-quality, and low-complexity host reads. Non-human reads were aligned to 18 the NCBI nucleotide and protein databases (NCBI Index Date: 06-02-2024) using GSNAPL and 19 RAPSearch. Post-filtering, sequences were aligned to the NCBI nucleotide (NT) database with Minimap2²⁰ and the NCBI protein (NR) database with Diamond²¹. Hits were annotated with 20 21 accession numbers, and taxon counts were generated from GSNAP and RAPSearch results.

22

SPAdes was used for de novo (without reference) genome assembly. The original reads were
 mapped to assembled contigs with Bowtie2. BLAST analysis was then conducted on the contigs
 against the Nucleotide NT-BLAST database (GSNAP) and the Protein NR database
 (RAPSearch2).

27

28 2.5. AMR pipeline

For AMR analysis CZID's AMR Pipeline v1.4.2²² was used. AMR gene detection is performed using the Resistance Gene Identifier (RGI) tool. The Comprehensive Antibiotic Resistance Database (CARD) v3.2.6²³ was used to identify AMR genes and pathogen species. Contigs of AMR genes are assembled using SPAdes and aligned with CARD through BLAST for species identification. The result files generated from this pipeline contain detailed information on AMR genes, quality control metrics, and pathogen-of-origin detection.

1

2 2.6. Statistical Analysis and Visualization

3 Python 3.10.12 was used for statistical analysis and visualization. The analysis used the 4 following Python packages: SciPy (version 1.13.1) for t-tests and ANOVA. statsmodels (version 0.14.4) for regression models and hypothesis testing. scikit-learn (version 1.5.2) was used for 5 6 PCA, PCoA, Multiple regression and additional statistical analysis. For data visualization, 7 matplotlib (version 3.7.1) was used. Seaborn (version 0.13.2) was used for statistical visualizations with heatmaps and violin plots. Interactive visualizations like the Sankey diagram 8 9 were created using Plotly (version 5.24.1). Data transformation tasks such as pivoting and log 10 transformation were handled with Pandas (version 2.2.2). Statistical analysis was performed 11 using numpy (version 1.26.4). The abundance metric of reads per million (RPM) was used for 12 statistical analysis and data visualisation.

13

14 3. Results

15 3.1. Summary of Sequencing Results

Metagenomic sequencing of SARS-CoV-2 (48 samples) and Control (47 samples) groups was done using the Illumina NextSeq550 platform. The SARS-CoV-2 group generated an average of 7.26 ± 1.52 million reads, out of which 25% (1.78 ± 0.56 million reads) passed the human filter. The control group had generated average 6.52 ± 3.47 million reads out of which 15% ($0.78 \pm$ 0.37 million reads) passed the human filter. One sample from the control group was not included in the study due to quality check failure before sequencing.

22

23 3.2. AMR Gene Alpha Diversity Analysis

The violin plots (Figure 1) show that the SARS-CoV-2 group has significantly higher species richness than the control group. This is reflected by the Chao diversity index (p = 0.01651), implying that the SARS-CoV-2 group harbors more distinct taxa. However, the Shannon and Simpson diversity indices show no significant differences between the groups (p = 0.98515 and p = 0.90225, respectively). This indicates that while the SARS-CoV-2 group has greater species richness, the overall distribution and balance of species abundances are similar to those in the control group.

31

32 3.3. AMR Gene Beta Diversity: Bray-Curtis Dissimilarity and PCoA Analysis

33 The Bray-Curtis dissimilarity heatmap (Figure 2) shows distinct clustering of SARS-CoV-2 (red

34 sample tags) and control (blue sample tags) samples. Significant within-group similarity in both

groups was observed, as indicated by lighter shades. The higher dissimilarity between groups is
 seen in the off-diagonal regions. The diagonal line represents zero dissimilarity. The Bray-Curtis
 dissimilarity heatmap highlights clear within-group similarities and significant between-group
 differences in AMR profiles.

5

6 **(Figure 3)** represents PCA (left) and PCoA (right) plots comparing SARS-CoV-2 (red) and 7 Control (blue) groups. In the PCA plot, PC1 (77.90% variance) and PC2 (7.91% variance) 8 reveal that the control group is tightly clustered near the origin. While, the SARS-CoV-2 group 9 shows a greater spread along PC1. In the PCoA plot, Axis 1 (32.79% variance) and Axis 2 10 (13.42% variance) show the control group forming a compact cluster. In contrast, the points in 11 the SARS-CoV-2 group are more scattered. The groups are clearly distinct along Axis 1 in both 12 plots, with SARS-CoV-2 exhibiting higher variations.

13

3.4. Differences in Resistome and Pathogen profiles among SARS-CoV-2 and Control Groups

Antimicrobial resistance (AMR) gene abundance and pathogen profiles were significantly differing among the SARS-CoV-2 and control groups. (Figure 4) presents a heatmap of statistically significant (p < 0.05, Mann-Whitney) AMR genes. It was observed that the SARS-CoV-2 group exhibited a higher density and more consistent abundance of genes such as *mecA, blaOXA-48*, and *blaNDM-1*. Meanwhile, the control group showed sparse and less pronounced patterns of AMR gene abundance.

(Figure 5) shows species-specific resistome profiles using a heatmap visualization. Significant associations between AMR genes and microbial species were observed in the SARS-CoV-2 group. Higher abundances of resistance genes were found in species such as *Klebsiella pneumoniae, Escherichia coli*, and *Staphylococcus aureus*. The control group exhibited weaker associations and lower resistance gene abundances. The AMR genes in the control group were primarily linked to species like *Acinetobacter baumannii* and *Pseudomonas aeruginosa*.

The Sankey diagram (Figure 6) showed the distribution of AMR genes within high-priority ESKAPE pathogens and their relative abundances among sample groups. Each ribbon represents an AMR gene, with the width proportional to its abundance (RPM). This reveals distinct differences in the distribution of AMR genes between the two groups. The SARS-CoV-2 group showing a larger diversity and higher abundance of ESKAPE-associated AMR genes.

1 3.5. Differential Abundance of AMR Genes

The volcano plot (Figure 7) displays the differential abundance of AMR (antimicrobial resistance) genes between the SARS-CoV-2 and Control groups. This representation is based on log2 fold change on (x-axis) and statistical significance (-log10 p-value), on y-axis). Genes with log2 fold change > 1 and Mann-Whitney p-values < 0.05 are highlighted in red as significant. Dashed lines in the figure represent thresholds for significance. Horizontal dashed line for the p-value (0.05) and vertical for log2 fold change (±1). The results show that most of the statistically significant genes are more abundant in the SARS-CoV-2 group.

9

10 **3.6. Bayesian Regression Analysis**

11 The Shapiro-Wilk test confirms that the data is not normally distributed in both groups. For Control. the statistic is 0.108 ($p = 2.76 \times 10^{-49}$), and for SARS-CoV-2 data, the statistic is 0.136 12 13 with (p 2.74×10^{-43}). For Shapiro-Wilk p<0.05 indicates a non-normal distribution of the data. 14 These results align with the skewed distributions seen in the histograms and Q-Q plots (Figure 15 8). Due to this non-normal distribution of data, the Bayesian regression model was used to 16 examine the factors influencing antimicrobial resistance (AMR) gene abundance. The model 17 has considered variables such as Sample Type (SARS-CoV-2 vs. Control), Collection Location, 18 Host Sex, and Host Age. The model results showed that SARS-CoV-2 samples had significantly 19 higher AMR gene abundance compared to control samples ($\beta = 1.549$, HDI [1.409, 1.691]).

Females had significantly higher AMR gene abundance ($\beta = 0.261$, HDI [0.167, 0.350]) than males. The variable of host age showed no significant effect on AMR gene abundance. The model summary and categorical mappings are elaborated in **(Table 1)** Trace plots **(Figure 9)** showed good parameter mixing and no divergences. The posterior predictive checks confirmed the alignment between model predictions and observed data **(Figure 10)**.

25

Categories	mean	SD	hdi_2.5%	hdi_97.5%	mcse_mean	mcse_sd	ess_bulk	ess_tail	r_hat
Beta_Collection_Location[0]	-0.157	0.091	-0.328	0.031	0.001	0.001	4719	2997	1
Beta_Collection_Location[1]	-0.182	0.104	-0.38	0.03	0.002	0.001	4634	3050	1
Beta_Collection_Location[2]	-1.316	0.421	-2.131	-0.489	0.005	0.004	6093	2935	1
Beta_Collection_Location[3]	-0.84	0.119	-1.07	-0.6	0.002	0.001	3881	2540	1
Beta_Host_Age	0	0.001	-0.003	0.002	0	0	3115	2795	1
Beta_Host_Sex[0]	0.26	0.048	0.168	0.353	0.001	0	4800	2561	1

Beta_Sample_Type[0]	1.516	0.051	1.415	1.612	0.001	0.001	4036	2833	1
Intercept	-0.489	0.051	-0.584	-0.389	0.001	0.001	2892	2752	1
Sigma	1.719	0.015	1.69	1.75	0	0	4898	2618	1
Categorical Mappings									
Beta_Sample_Type	Beta_Collection_ Location	Beta_Host_ Sex							
Control (Reference)	Nagpur (Reference)	Male (Reference)							
SARS-CoV-2 [0]	Chandrapur [0]	Female [0]							
	Gadchiroli [1]								
	Wardha [2]								
	Bhandara [3]								

1

2 **Table 1:** Summary of Bayesian regression model results for the effect of age, location, sex, and sample

3 type on AMR gene abundance. Along with categorical mappings. Summary metrics include mean effects,

4 standard deviation (SD), highest density intervals (HDI), Monte Carlo standard errors (MCSE), effective

5 sample sizes (ESS), and convergence diagnostic (*R*-hat) to evaluate model reliability and convergence.

6

7 3.7. Antimicrobial Resistance Genes and Their Associated Drug Classes

8 The significant resistance genes as per volcano plot threshold (log2FC > 1 and Mann-Whitney 9 p-values < 0.05) were analysed for their associated drug classes. The CARD database was 10 used to attribute drug classes to gene families. The data includes 38 drug classes and 60 11 unique resistance genes. Some drug classes were linked to multiple genes, such as 12 aminoglycoside antibiotics, which include AAC(3)-IIc, AAC(3)-IIe, ANT(2")-Ia, ANT(4')-Ib, 13 APH(3")-lb, APH(6)-ld, and acrD. In contrast, others, like fluoroquinolone antibiotics and 14 macrolide antibiotics, also have several resistance genes. Fewer genes represent drug classes such as mupirocin-like antibiotics and peptide antibiotics. Genes like ToIC and MexB contribute 15

16 to resistance within specific classes. **(Table 2)**

S. No.	drug_class	gene_name	gene_count
1	aminocoumarin antibiotic	mdtA, mdtB, mdtC	3
2	aminoglycoside antibiotic	AAC(3)-IIc, AAC(3)-IIe, ANT(2")-Ia, ANT(4')-Ib, APH(3")-Ib, APH(6)-Id, acrD	7
3	aminoglycoside antibiotic; aminocoumarin antibiotic	baeS, cpxA	2
4	disinfecting agents and antiseptics	OpmH, qacJ	2

5	fluoroquinolone antibiotic	emrA	1
6	fluoroquinolone antibiotic; aminoglycoside antibiotic	сеоВ	1
7	fluoroquinolone antibiotic; aminoglycoside antibiotic; penam; tetracycline antibiotic; disinfecting agents and antiseptics	mdeA	1
8	fluoroquinolone antibiotic; cephalosporin; glycylcycline; penam; tetracycline antibiotic; rifamycin antibiotic; phenicol antibiotic; disinfecting agents and antiseptics	acrB	1
9	fluoroquinolone antibiotic; cephalosporin; penam; tetracycline antibiotic; peptide antibiotic; disinfecting agents and antiseptics	mgrA	1
10	fluoroquinolone antibiotic; diaminopyrimidine antibiotic; phenicol antibiotic	MexF	1
11	fluoroquinolone antibiotic; disinfecting agents and antiseptics	norA	1
12	fluoroquinolone antibiotic; glycylcycline; tetracycline antibiotic; diaminopyrimidine antibiotic; nitrofuran antibiotic	oqxB	1
40		Manual	4
13	fluoroquinoione antibiotic; tetracycline antibiotic; disinfecting agents and antiseptics		1
14	glycylcycline; tetracycline antibiotic	adeB	1
15	lincosamide antibiotic; streptogramin antibiotic; pleuromutilin antibiotic	IsaC	1
16	macrolide antibiotic; disinfecting agents and antiseptics	Acinetobacter baumannii AmvA	1
17	macrolide antibiotic; fluoroquinolone antibiotic; aminoglycoside antibiotic; carbapenem; cephalosporin; glycylcycline; cephamycin; penam; tetracycline antibiotic; peptide antibiotic; aminocoumarin antibiotic; rifamycin antibiotic; phenicol antibiotic; penem; disinfecting agents and antiseptics	TolC	1
18	macrolide antibiotic; fluoroquinolone antibiotic; aminoglycoside antibiotic; carbapenem; cephalosporin; penam; peptide antibiotic; penem	Klebsiella pneumoniae KpnH	1
19	macrolide antibiotic; fluoroquinolone antibiotic; lincosamide antibiotic; carbapenem; cephalosporin; tetracycline antibiotic; rifamycin antibiotic; diaminopyrimidine antibiotic; phenicol antibiotic; penem	adeJ, adeK	2
20	macrolide antibiotic; fluoroquinolone antibiotic; monobactam; aminoglycoside antibiotic; carbapenem; cephalosporin; cephamycin; penam; tetracycline antibiotic; phenicol antibiotic; penem; disinfecting agents and antiseptics	ParR	1
21	macrolide antibiotic; fluoroquinolone antibiotic; monobactam; carbapenem; cephalosporin; cephamycin; penam; tetracycline antibiotic; peptide antibiotic; aminocoumarin antibiotic; diaminopyrimidine antibiotic; sulfonamide antibiotic; phenicol antibiotic; penem	MexB	1
22	macrolide antibiotic; fluoroquinolone antibiotic; penam	gadX, mdtE, mdtF	3
23	macrolide antibiotic: fluoroquinolone antibiotic: penam: tetracycline antibiotic	evaS	1
	macrolide antibiotic; fluoroquinolone antibiotic; tetracycline antibiotic; phenicol		
24	macrolide antibiotic; lincosamide antibiotic; streptogramin antibiotic; streptogramin A		1
25	aniubiouc; streptogramin B antibiotic		2
26	macrolide antibiotic; monopactam; tetracycline antibiotic; aminocoumarin antibiotic		1
27	macrolide antibiotic; streptogramin antibiotic	msie MovK	1
28	macronue antibiotic; tetracycline antibiotic; disinfecting agents and antiseptics		1
29	monopaciam, cepnaiosporin; penam; penem	I EIVI-110 Difidobostorium bifidum ils0	1
30	mupirocin-like antibiotic	resistance to mupirocin	1
31	nitroimidazole antibiotic	msbA	1
32	nucleoside antibiotic; disinfecting agents and antiseptics	mdtO, mdtP	2
33	peptide antibiotic	Yojl, bacA, ugd	3
34	peptide antibiotic; aminocoumarin antibiotic; rifamycin antibiotic	LptD	1
35	phenicol antibiotic	Agrobacterium fabrum chloramphenicol	3

		acetyltransferase, cmIA9, floR	
36	phosphonic acid antibiotic	mdtG	1
37	rifamycin antibiotic	Bifidobacterium adolescentis rpoB mutants conferring resistance to rifampicin, rpoB2	2
38	tetracycline antibiotic	emrY, tet(G), tet(Q)	3

Table 2: Significant AMR genes and their associated drug classes, highlighting genes contributing to
 resistance across multiple drug classes.
 3

- 4
- 5

6 4. Discussion

Multiple studies around the world have investigated the compositional dynamics of URT 7 8 microbiome in SARS-CoV-2 infected individuals. These studies primarily focused on explaining 9 the relationships between the URT microbiome composition and factors like disease severity, risk of developing secondary infections and utility of URT microbiome as a marker to predict 10 disease outcomes.^{24,25,26} It is now widely agreed upon that the SARS-CoV-2 infection have a 11 12 role in altering the URT microbiome. However, the impact of infection on the AMR dynamics in 13 the URT needs to be further looked into. Understanding the changes in AMR profiles in context 14 with SARS-CoV-2 infection is significant for preventing secondary bacterial infection involving 15 the lower respiratory tract and lungs. Understanding AMR dynamics could also be instrumental 16 in devising effective therapeutics and management strategies for COVID-19 patients.

17

Stefanini et al. (2021)²⁷ (Hoque et al., 2021)²⁸ reported that SARS-CoV-2 infection is associated 18 19 with higher diversity and increased abundance of AMR genes, suggesting a more complex 20 microbial ecosystem or dysbiosis. The findings of our study also suggest that SARS-CoV-2 21 infection could be linked with a higher diversity and abundance of AMR genes. The sequencing 22 results indicated a substantial number of reads generated for both groups. However, filtering for 23 human reads significantly reduced microbial reads, particularly in the control group. This 24 reduction of microbial reads may indicate a less abundant microbial community in the URT. The 25 higher number of microbial reads in the SARS-CoV-2 samples indicates towards a relatively 26 complex microbial ecosystem in the URT or a potential dysbiosis of the host microbiome due to 27 the viral infection.

The Chao1 index demonstrated that the SARS-CoV-2 group had a greater richness of AMR genes than the control group. This finding converges with previous studies indicating that viral

infections can influence the composition and diversity in the context of gut²⁹ and URT³⁰ microbiomes. The non-significant differences in the Shannon and Simpson indices suggest that the SARS-CoV-2 group has a diverse resistome, but the evenness of these distributions is similar to that of the control group. This finding indicates that the higher AMR richness in the SARS-CoV-2 group is not due to the skewed abundance of a few AMR genes.

Abundance of the antimicrobial resistance (AMR) genes substantially differed between SARS-COV-2 infected patients and the control group. PCA and PCoA analyses revealed distinct clustering between these two groups. Control samples exhibited lower variability in clustering, which suggests the presence of a stable and uniform resistome. Meanwhile, the SARS-CoV-2 group displayed higher variability, suggesting an active alteration of the microbial communities within the infected patients due to secondary infections, antibiotic therapies, or changes in the microbiome due to the infection.

Bray-Curtis dissimilarity further indicated the separation between the two groups. The heatmap shows the significant impact of SARS-CoV-2 infection on microbial community composition and resistome profiles. The SARS-CoV-2 group exhibited a significantly higher abundance of critical AMR genes, such as mecA, blaOXA-48, and blaNDM-1. These genes confer resistance to key antibiotics like beta-lactams and carbapenems. Elevated abundance of these critical AMR genes raises concerns about potential multidrug-resistant secondary bacterial infections in COVID-19 patients.

Pathogen-specific AMR analysis using CARD revealed stronger associations of these AMR genes with pathogens such as *Klebsiella pneumoniae*, *Escherichia coli*, and *Staphylococcus aureus* in the URT of SARS-CoV-2 patients. This finding underscores the increased risk of secondary infections, exacerbated by prolonged hospital stays, invasive procedures like intubation, or immune dysregulation during SARS-CoV-2 infections. Meanwhile, in the control group, AMR genes were primarily linked to *Acinetobacter baumannii* and *Pseudomonas aeruginosa* but at lower abundances than the SARS-CoV-2 group.

Bayesian regression analysis showed that SARS-CoV-2 infection is an important factor contributing towards increased AMR gene abundance; this finding aligns with previous studies where SARS-CoV-2 patients showed elevated AMR profiles^{31,32,33}. Intriguingly, the analysis identified higher AMR gene abundance in females than in males. This finding still leaves the scope for further validation through large-scale studies that incorporate the participants' behavioural and socio-economic variables. It is also important to highlight that in India, females tend to self-medicate more as compared to males^{34,35}. The observed higher prevalence of AMR in females could also be due to this behavioural pattern. In this study we did not observe significant age-associated variations in AMR abundance and diversity. Our findings diverge from previous studies where age is identified as a significant factor contributing to AMR diversity^{36,37}. The age-related paradigms may further be explored in larger longitudinal studies specifically designed to ascertain these effects.

8 The resistome analysis also revealed broad resistance across multiple antibiotic classes, 9 including aminoglycosides, macrolides, and fluoroquinolones. These findings highlight the 10 complexities of managing secondary bacterial infections in COVID-19 patients, particularly in 11 the context of multidrug-resistant pathogens.

12

13 Conclusion

The findings of this study highlight the need for monitoring the dynamics of AMR in SARS-CoV-2 patients. In clinical settings, secondary bacterial infections and multidrug-resistant pathogens make pandemics like COVID-19 difficult to manage. Policymakers should look forward to incorporate AMR surveillance into public health workflows. Sufficient resources must be allocated towards large-scale AMR surveillance in a populous and developing country like India. Collaboration among healthcare providers, researchers, and public health authorities is crucial to safeguarding the efficacy of antibiotic treatments and ensuring better patient outcomes.

21 Limitations of the Study

The cross-sectional study design limits the ability to understand temporal changes in AMR gene profiles. Additionally, the potential impacts of antibiotic usage on AMR profiles could not be assessed in this study, as this is a retrospective study and antibiotic usage data were not collected when the samples were originally obtained for SARS-CoV-2 genome surveillance under the INSACOG mandate.

27

28

1	
2	
3	
4	
4	
5	
6	
7	Figure Legends
8	
9	Figure 1: Chao1, Shannon, and Simpson Diversity of AMR Genes: Chao1 diversity (left),
10	Shannon diversity (center), and Simpson diversity (right). Chao1 diversity (p=0.01651),
11	Shannon ($p = 0.98515$), and Simpson ($p = 0.90225$)
12	
13	Figure 2: Bray-Curtis Dissimilarity Heatmap: The heatmap shows SARS-CoV-2 samples
14	(Sample IDs in red) and control samples (Sample IDs in blue). Red shades of heatmap
15	represent dissimilarity, while blue represents similarity. The diagonal represents perfect
16	similarity (self-comparison), indicated in dark blue.
17	
18	Figure 3: PCA (left) and PCoA (right) plots showing the clustering of AMR gene profiles in
19	control and SARS-CoV-2 groups. PCA (PC1: 77.90% variance) and PCoA (Axis 1: 32.79%
20	variance) both show distinct separation between the groups.
21	
22	Figure 4: Compositional Variations in the abundance of AMR Genes Among Control and
23	SARS-CoV-2 Groups (Log-Transformed Significant Genes). Each row represents a distinct
24	AMR gene, and each column represents a sample. The color intensity reflects gene abundance,
25	with darker colors indicating higher abundance.
26	
27	Figure 5: Variations in the Abundance of Species-associated AMR Genes Among Control and
28	SARS-CoV-2 Groups (Log-Transformed) The heatmaps display log-transformed read counts
29	per million (RPM).
30	

Figure 6: Sankey Diagram Showing the Relationship Between High-Priority ESKAPE
 Pathogens and AMR Genes in SARS-CoV-2 and Control Groups. The width of the flows
 between species and AMR genes indicates the abundance in RPM.

4

Figure 7: Volcano plot of AMR gene abundance changes between SARS-CoV-2 and control
samples, based on a Mann-Whitney U test. The x-axis represents log2 fold change (positive for
SARS-CoV-2, negative for control), and the y-axis shows -log10 p-values, with higher values
indicating statistical significance. Points above the dashed line at -log10(0.05) are significant (p
< 0.05). Gens with |log2 fold change| > 1 and p-value < 0.05 are highlighted in red.

10

Figure 8: Distributions of antimicrobial resistance gene families in control (top) and SARS-CoV2 (bottom) groups. Histograms (left). Q-Q plots (right) reveal deviations from normality, with
heavier tails in both groups.

14

15 Figure 9: estimates coefficients: Left panels show posterior density for 16 Beta_Collection_Location, Beta_Host_Age, Beta_Host_Sex, Beta_Sample_Type, Intercept, and 17 Sigma. Solid lines indicate posterior densities, while dashed lines represent prior distributions. Right panels display corresponding trace plots of parameter values across iterations, 18 19 demonstrating adequate mixing and convergence for all parameters.

20

Figure 10: Posterior predictive check comparing observed data (black line) with the posterior predictive distribution (blue line) and its mean (orange dashed line). The alignment of the observed and predicted distributions indicates the model's ability to capture the underlying data trends.

25

26

27

28 29

30

31

- 1

 2

 3

 4

 5
- 6

7 Data availability statement

8 The data is available as supplementary data with the file name 9 "combined supplementary data" Any additional data, if required, will be made available on 10 request by the authors.

11 Author declaration

12 The authors assure that the research has followed all ethical guidelines and received approvals

13 from the Institutional Ethics Committee for Research on Human Subjects (IEC) of CSIR-NEERI,

14 Nagpur-20, India. Necessary consent from patients/participants has been obtained, and relevant

15 institutional documentation has been archived.

16 **Confidentiality declaration**

Sample IDs (23G214-5G-264_S1 to 23G214-5G-311_S48 and 24D214-5G_387_S45 to
24D214-5G_434_S91) are masked IDs and cannot be traced to participant details. The precise
age of the participants is masked, and non-overlapping age ranges were used.

20 Author contribution statement

SST and KK have contributed equally to the conceptualization, experimentation, and dataanalysis of this study.

23 **Conflict of interest statement**

24 The authors declare no conflict of interest.

1 Acknowledgement

- 2 The authors are thankful to CSIR-NEERI for providing funds under project OLP-57 (March 2023
- 3 -April 2024) for conducting this study. This manuscript has obtained the approval of the
- 4 Knowledge Resource Center (KRC) publication committee of CSIR-NEERI (KRC No.: CSIR-

5 NEERI/KRC/2024/NOV/EEPM/1) Date: 14-11-2024

- 6
- 7

8 References

- Ramamurthy, T., Ghosh, A., Chowdhury, G., Mukhopadhyay, A. K., Dutta, S., & Miyoshi, S.
 (2022). Deciphering the genetic network and programmed regulation of antimicrobial resistance in
 bacterial pathogens. Frontiers in Cellular and Infection Microbiology, 12, 952491.
 https://doi.org/10.3389/fcimb.2022.952491
- Kessler, C., Hou, J., Neo, O., & Buckner, M. (2022). In situ, in vivo, and in vitro approaches for
 studying AMR plasmid conjugation in the gut microbiome. FEMS Microbiology Reviews, 47.
 <u>https://doi.org/10.1093/femsre/fuac044</u>.
- Boerlin, P., & Reid-Smith, R. (2008). Antimicrobial resistance: its emergence and transmission.
 Animal Health Research Reviews, 9, 115 126. <u>https://doi.org/10.1017/S146625230800159X</u>.
- Hanada, S., Pirzadeh, M., Carver, K., & Deng, J. (2018). Respiratory Viral Infection-Induced
 Microbiome Alterations and Secondary Bacterial Pneumonia. Frontiers in Immunology, 9.
 <u>https://doi.org/10.3389/fimmu.2018.02640</u>.
- Tan, K., Lim, R., Liu, J., Ong, H., Tan, V., Lim, H., Chung, K., Adcock, I., Chow, V., & Wang, D.
 (2020). Respiratory Viral Infections in Exacerbation of Chronic Airway Inflammatory Diseases:
 Novel Mechanisms and Insights From the Upper Airway Epithelium. Frontiers in Cell and
 Developmental Biology, 8. https://doi.org/10.3389/fcell.2020.00099.
- Bottery, M., Pitchford, J., & Friman, V. (2020). Ecology and evolution of antimicrobial resistance in
 bacterial communities. The ISME Journal, 15, 939 948. <u>https://doi.org/10.1038/s41396-020-</u>
 <u>00832-7</u>.
- 7. Despotovic, M., De Nies, L., Busi, S. B., & Wilmes, P. (2023). Reservoirs of antimicrobial
 resistance in the context of One Health. Current Opinion in Microbiology, 73, 102291.
 https://doi.org/10.1016/j.mib.2023.102291
- Segala, F. V., Bavaro, D. F., Di Gennaro, F., Salvati, F., Marotta, C., Saracino, A., Murri, R., &
 Fantoni, M. (2021). Impact of SARS-CoV-2 Epidemic on Antimicrobial Resistance: A Literature
 Review. Viruses, 13(11), 2110. <u>https://doi.org/10.3390/v13112110</u>

1	9.	Sender, V., & Hentrich, K. (2021). Virus-Induced Changes of the Respiratory Tract Environment
2		Promote Secondary Infections With Streptococcus pneumoniae. Frontiers in Cellular and
3		Infection Microbiology, 11, 643326. https://doi.org/10.3389/fcimb.2021.643326
4	10.	World Health Organization: WHO. (2024, April 26). WHO reports widespread overuse of
5		antibiotics in patients hospitalized with COVID-19. World Health Organization.
6		https://www.who.int/news/item/26-04-2024-who-reports-widespread-overuse-of-antibiotics-in-
7		patientshospitalized-with-covid-
8		$\underline{19\#:}{\sim}:text=Highest\%20 rate\%20 of\%20 antibiotic\%20 use, the\%20 A frican\%20 Region\%20 (79\%25).$
9	11.	Fazel, P., Sedighian, H., Behzadi, E., Kachuei, R., & Fooladi, A. a. I. (2023). Interaction between
10		SARS-COV-2 and pathogenic bacteria. Current Microbiology, 80(7).
11		https://doi.org/10.1007/s00284-023-03315-y
12	12.	Rehman, S. (2023). A parallel and silent emerging pandemic: Antimicrobial resistance (AMR)
13		amid COVID-19 pandemic. Journal of Infection and Public Health, 16(4), 611-617.
14		https://doi.org/10.1016/j.jiph.2023.02.021
15	13.	Mac Aogáin, M., Lau, K. J. X., Cai, Z., Narayana, J. K., Purbojati, R. W., Drautz-Moses, D. I.,
16		Gaultier, N. E., Jaggi, T. K., Tiew, P. Y., Ong, T. H., Koh, M. S., Hou, A. L. Y., Abisheganaden, J.
17		A., Tsaneva-Atanasova, K., Schuster, S. C., & Chotirmall, S. H. (2020). Metagenomics reveals a
18		core macrolide resistome related to microbiota in chronic respiratory disease. American Journal
19		of Respiratory and Critical Care Medicine, 202(3), 433-447. https://doi.org/10.1164/rccm.201911-
20		<u>2202oc</u>
21	14.	Nath, S., Sarkar, M., Maddheshiya, A., De, D., Paul, S., Dey, S., Pal, K., Roy, S. K., Ghosh, A.,
22		Sengupta, S., Paine, S. K., Biswas, N. K., Basu, A., & Mukherjee, S. (2023). Upper respiratory
23		tract microbiome profiles in SARS-CoV-2 Delta and Omicron infected patients exhibit variant
24		specific patterns and robust prediction of disease groups. Microbiology Spectrum, 11(6).
25		https://doi.org/10.1128/spectrum.02368-23
26	15.	QIASEq FX DNA Library Kit. (2023). Qiagen.com. https://www.qiagen.com/zh-
27		us/products/discovery-and-translational-research/next-generation-
28		sequencing/metagenomics/qiaseq-fx-dna-library-kit
29	16.	Langmead, B., & Salzberg, S. L. (2012). Fast gapped-read alignment with Bowtie 2. Nature
30		Methods, 9(4), 357-359. https://doi.org/10.1038/nmeth.1923
31	17.	Chen, S. (2023). Ultrafast one-pass FASTQ data preprocessing, quality control, and
32		deduplication using fastp. IMeta, 2(2), e107. https://doi.org/10.1002/imt2.107
33	18.	Kim, D., Paggi, J. M., Park, C., Bennett, C., & Salzberg, S. L. (2019). Graph-based genome
34		alignment and genotyping with HISAT2 and HISAT-genotype. Nature Biotechnology, 37(8), 907-
35		915. https://doi.org/10.1038/s41587-019-0201-4

1	19. Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M.,
2	& Gingeras, T. R. (2012). STAR: ultrafast universal RNA-seq aligner. Bioinformatics, 29(1), 15-
3	21. https://doi.org/10.1093/bioinformatics/bts635
4	20. Li, H. (2018). Minimap2: Pairwise alignment for nucleotide sequences. Bioinformatics, 34(18),
5	3094-3100. https://doi.org/10.1093/bioinformatics/bty191
6	21. Buchfink, B., Xie, C., & Huson, D. H. (2014). Fast and sensitive protein alignment using
7	DIAMOND. Nature Methods, 12(1), 59-60. https://doi.org/10.1038/nmeth.3176
8	22. Langelier, C., Lu, D., Kalantar, K., Chu, V., Glascock, A., Guerrero, E., Bernick, N., Butcher, X.,
9	Ewing, K., Fahsbender, E., Holmes, O., Hoops, E., Jones, A., Lim, R., McCanny, S., Reynoso, L.,
10	Rosario, K., Tang, J., Valenzuela, O., McArthur, A. (2024). Simultaneous detection of
11	pathogens and antimicrobial resistance genes with the open source, cloud-based, CZ ID pipeline.
12	Research Square (Research Square). https://doi.org/10.21203/rs.3.rs-4271356/v1
13	23. Alcock, B. P., Huynh, W., Chalil, R., Smith, K. W., Raphenya, A. R., Wlodarski, M. A.,
14	Edalatmand, A., Petkau, A., Syed, S. A., Tsang, K. K., Baker, S. J. C., Dave, M., McCarthy, M.
15	C., Mukiri, K. M., Nasir, J. A., Golbon, B., Imtiaz, H., Jiang, X., Kaur, K., McArthur, A. G.
16	(2022). CARD 2023: expanded curation, support for machine learning, and resistome prediction
17	at the Comprehensive Antibiotic Resistance Database. Nucleic Acids Research, 51(D1), D690-
18	D699. https://doi.org/10.1093/nar/gkac920
19	24. De Maio, F., Posteraro, B., Ponziani, F. R., Cattani, P., Gasbarrini, A., & Sanguinetti, M. (2020).
20	Nasopharyngeal microbiota profiling of SARS-COV-2 infected patients. Biological Procedures
21	Online, 22(1). https://doi.org/10.1186/s12575-020-00131-7
22	25. Rhoades, N. S., Pinski, A. N., Monsibais, A. N., Jankeel, A., Doratt, B. M., Cinco, I. R., Ibraim, I.,
23	& Messaoudi, I. (2021). Acute SARS-CoV-2 infection is associated with an increased abundance
24	of bacterial pathogens, including Pseudomonas aeruginosa in the nose. Cell Reports, 36(9),
25	109637. https://doi.org/10.1016/j.celrep.2021.109637
26	26. Ventero, M. P., Moreno-Perez, O., Molina-Pardines, C., Paytuví-Gallart, A., Boix, V., Escribano,
27	I., Galan, I., González-delaAleja, P., López-Pérez, M., Sánchez-Martínez, R., Merino, E., &
28	Rodríguez, J. C. (2022). Nasopharyngeal Microbiota as an early severity biomarker in COVID-19
29	hospitalised patients. Journal of Infection, 84(3), 329-336.
30	https://doi.org/10.1016/j.jinf.2021.12.030
31	27. Stefanini, I., De Renzi, G., Foddai, E., Cordani, E., & Mognetti, B. (2021). Profile of Bacterial
32	Infections in COVID-19 Patients: Antimicrobial Resistance in the Time of SARS-CoV-2. Biology,
33	10(9), 822. https://doi.org/10.3390/biology10090822
34	28. Hoque, M. N., Sarkar, M. M., Rahman, M. S., Akter, S., Banu, T. A., Goswami, B., Jahan, I.,
35	Hossain, M. S., Shamsuzzaman, A. K., Nafisa, T., Molla, M. M., Yeasmin, M., Ghosh, A. K.,
36	Osman, E., Alam, S. K., Uzzaman, M. S., Habib, M. A., Mahmud, A. S., Crandall, K. A.,
37	Khan, M. S. (2021). SARS-CoV-2 infection reduces human nasopharyngeal commensal

1		microbiome with inclusion of pathobionts. Scientific Reports, 11(1), 1-17.
2		https://doi.org/10.1038/s41598-021-03245-4
3	29.	Li, J., Jing, Q., Li, J., Hua, M., Di, L., Song, C., Huang, Y., Wang, J., Chen, C., & Wu, A. R.
4		(2023). Assessment of microbiota in the gut and upper respiratory tract associated with SARS-
5		CoV-2 infection. Microbiome, 11(1). <u>https://doi.org/10.1186/s40168-022-01447-0</u>
6	30.	Shilts, M. H., Rosas-Salazar, C., Strickland, B. A., Kimura, K. S., Asad, M., Sehanobish, E.,
7		Freeman, M. H., Wessinger, B. C., Gupta, V., Brown, H. M., Boone, H. H., Patel, V., Barbi, M.,
8		Bottalico, D., O'Neill, M., Akbar, N., Rajagopala, S. V., Mallal, S., Phillips, E., Das, S. R.
9		(2022). Severe COVID-19 is associated with an altered upper respiratory tract microbiome.
10		Frontiers in Cellular and Infection Microbiology, 11. https://doi.org/10.3389/fcimb.2021.781968
11	31.	Bauer, K., Puzniak, L., Yu, K., Klinker, K., Watts, J., Moise, P., Finelli, L., Ai, C., & Gupta, V.
12		(2022). A Multicenter Comparison of Prevalence and Predictors of Antimicrobial Resistance in
13		Hospitalized Patients Before and During the Severe Acute Respiratory Syndrome Coronavirus 2
14		Pandemic. Open Forum Infectious Diseases, 9. https://doi.org/10.1093/ofid/ofac537.
15	32.	Kariyawasam, R., Julien, D., Jelinski, D., Larose, S., Rennert-May, E., Conly, J., Dingle, T., Chen,
16		J., Tyrrell, G., Ronksley, P., & Barkema, H. (2021). Antimicrobial resistance (AMR) in COVID-19
17		patients: a systematic review and meta-analysis (November 2019–June 2021). Antimicrobial
18		Resistance and Infection Control, 11. https://doi.org/10.1186/s13756-022-01085-z.
19	33.	Saini, V., Jain, C., Singh, N., Alsulimani, A., Gupta, C., Dar, S., Haque, S., & Das, S. (2021).
20		Paradigm Shift in Antimicrobial Resistance Pattern of Bacterial Isolates during the COVID-19
21		Pandemic. Antibiotics, 10. https://doi.org/10.3390/antibiotics10080954.
22	34.	Juneja, K., Chauhan, A., Shree, T., Roy, P., Bardhan, M., Ahmad, A., Pawaiya, A. S., & Anand,
23		A. (2024). Self-medication prevalence and associated factors among adult population in Northern
24		India: A community-based cross-sectional study. SAGE Open Medicine.
25		https://doi.org/10.1177/20503121241240507
26	35.	Rathod, P., Sharma, S., Ukey, U., Sonpimpale, B., Ughade, S., Narlawar, U., Gaikwad, S., Nair,
27		P., Masram, P., & Pandey, S. (2023). Prevalence, Pattern, and Reasons for Self-Medication: A
28		Community-Based Cross-Sectional Study From Central India. Cureus, 15(1), e33917.
29		https://doi.org/10.7759/cureus.33917
30	36.	Chu, V., Kalantar, K., Mick, E., Tsitsiklis, A., Spottiswoode, N., Derisi, J., Ambroggio, L., Mourani,
31		P., & Langelier, C. (2023). Antimicrobial Resistance in the Upper Respiratory Tract of Children
32		Compared with Adults. Journal of the Pediatric Infectious Diseases Society.
33		https://doi.org/10.1093/jpids/piad070.005.
34	37.	Langelier, C., Chu, V., Tsitsiklis, A., Mick, E., Ambroggio, L., Kalantar, K., Glascock, A., Osborne,
35		C., Wagner, B., Matthay, M., Derisi, J., Calfee, C., & Mourani, P. (2023). The antibiotic resistance
36		reservoir of the lung microbiome expands with age. Research Square.
37		https://doi.org/10.21203/rs.3.rs-3283415/v1.



Bray-Curtis Dissimilarity Heatmap 23G214-5G-264_S1-23G214-5G-265_S2-23G214-5G-266_S3-23G214-5G-267_S4 -23G214-5G-268_S5 -23G214-5G-269_S6-23G214-5G-270_S7 -23G214-5G-271_S8-23G214-5G-272_S9-23G214-5G-273_S10-23G214-5G-274_S11 -23G214-5G-275_S12-23G214-5G-276_S13-23G214-5G-277_S14 -23G214-5G-278_S15 23G214-5G-279_S16-23G214-5G-280_S17 -



230214-30-301_330-	
23G214-5G-302_S39 -	
23G214-5G-303_S40 -	
23G214-5G-304_S41 -	
23G214-5G-305_S42 -	
23G214-5G-306_S43 -	
23G214-5G-307_S44 -	
23G214-5G-308_S45 -	
23G214-5G-309_S46 - ഗ	
<u>0</u> 23G214-5G-310_S47 -	
23G214-5G-311_S48 -	
ັດ 24D214-5G_387_S45 -	
24D214-5G_388_S46 -	
24D214-5G_389_S47 -	
24D214-5G_390_S48 -	
24D214-5G_391_S49 -	
24D214-5G_392_S50 -	
24D214-5G_393_S51 -	
24D214-5G_394_S52 -	
24D214-5G_395_S53 -	
24D214-5G_396_S54 -	
24D214-5G_397_S55 -	
24D214-5G_398_S56 -	
24D214-5G_399_S57 -	
24D214-5G_400_S58 -	
24D214-5G_401_S59 -	
24D214-5G_402_S60 -	
24D214-5G_403_S61 -	
24D214-5G_404_S62 -	
24D214-5G_405_S63 -	
24D214-5G_406_S64 -	
24D214-5G_407_S65 -	
24D214-5G 408 566 - medRXIV preprint doi: https://doi.org/10.1 (which was not certified by peer re	101/2024.11.14.24317312; this version posted December 5, 2024. The copyright holder for this preprint eview) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
24D214-5G_409_56 <i>I</i> ^t is	made available under a CC-BY-NC-ND 4.0 International license .
24D214-5G_410_S68-	
24D214-5G_411_S69 -	
24D214-5G_412_5/0-	
24D214-5G_413_S71-	
24D214-5G 414 S72-	



- 0.8

- 0.6

04

24D214-5G_415_S73-24D214-5G_416_S74 -24D214-5G_417_S75-24D214-5G_418_S76-24D214-5G_419_S77 -24D214-5G_420_S78-24D214-5G_421_S79 24D214-5G_422_S80-24D214-5G_423_S81 -24D214-5G_424_S82-24D214-5G_425_S83-24D214-5G_426_S84 24D214-5G_427_S85 -24D214-5G_428_S86-24D214-5G_429_S87 -24D214-5G_431_S88-24D214-5G_432_S89 24D214-5G_433_S90-24D214-5G_434_S91-



Samples

PCA Plot





Sample Name



Log-Transformed Gene Abundance (Control)





	Achromobacter xylosoxidans	-														
	Acinetobacter	-														
	Acinetobacter baumannin Acinetobacter haemolyticus	_														
	Acinetobacter johnsonii	-														
P	- 1.6 Acinetobacter pittii	-														
	Bifidobacterium animalis	-														
	Bifidobacterium breve Bifidobacterium dentium															
	Bifidobacterium longum	_														
	Brucella intermedia	-														
	Campylobacter coli	-														
	Citrobacter	-														
_	- 1.4 Citrobacter amaionaticus	-														
	Collinsella aerofaciens	-														
	Corynebacterium diphtheriae	-														
	Corynebacterium urealyticum	-														
	Eggerthella lenta Enterebactor	-														
	Enterobacter cloacae	_														
	Enterobacter hormaechei	-									Т					
	Enterococcus faecalis	-														1
	Escherichia	-														
	Escherichia coli Esocalibactorium prauspitzii	-														
	Fusobacterium nucleatum	_														
	Haemophilus influenzae	-														
	Klebsiella	-														
	Klebsiella michiganensis	-														
	Klebsiella pneumoniae	-								L			ш		L	
-	- 1.0 Micrococcus luteus	_														
	Moraxella catarrhalis	-														
	Moraxella osloensis	-														
	Neisseria meningitidis	-														
	n Nocardia farcinica	-														
	Pasteurella multocida	-														
	م Porphyromonas gingivalis	-														
-	- 0.8 Proteus mirabilis	-														
	Providencia heimbachae	-														
	Pseudomonas aeruginosa	_														
	Pseudomonas mendocina	-														
	Pseudomonas putida	-														
	Pseudomonas stutzeri	-														
	Raistonia mannitolilytica Pothia mucilagingsa	-														
_	- 0.6 Salmonella enterica	_														
	Shigella sonnei	-														
	Sphingobium yanoikuyae	-														
	Staphylococcus Staphylococcus	-														
	Staphylococcus alieuae Staphylococcus aureus	_														
	Staphylococcus epidermidis	-														
	Staphylococcus haemolyticus	-														
	Staphylococcus hominis	-														
	- 0.4 Staphylococcus lugdunensis	-														
	Stenotrophomonas maltophilia	_														
	Streptococcus	-														
	Streptococcus cristatus	-														
	Streptococcus gordonii	-														
	Streptococcus gwangjuense Streptococcus mitis															
	Streptococcus mutans	_														
	- 0.2 Streptococcus pneumoniae	-														
	Streptococcus pseudopneumoniae	-														
	Streptococcus pyogenes	-														
	Thalassospira indica	_														
	Vibrio	-														
	Vibrio cholerae	-														
	- 0.0 Vibrio parahaemolyticus	-			1	1							1		1	
		·lla	ein	<u>l</u> g	ő	19	21	23	0 <u>7</u> 0	·lla		aQ	'nT	3L)	۶ť	ЯЦ
		ю Ю	rot	(9)	Ċ	Ċ	V-1 U	C-7	Ċ	3").	1(6)	Ab	Ā)(MI	n tƙ	Ц
		AC	d اد	AC	∢	A	AD	AD	A	Ĕ	ЧРF	iin		ЗRР	tun	
		∢	onõ	∢						A	*	nar		ш	tria	
			Jcti									aur			ηs	
			ifuı									ir b			riui	
			d'c									lct∈			cte	





- 2.0 - 1.5 - 1.0 - 0.5

- 0.0

medRxiv preprint doi: https://doi.org/10.1101/2024.11.14.24317312; this version posted December 5, 2024. The copyright holder for this preprint Combined Rxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.









Cumulative Histogram (Control)



